


Indaptus Therapeutics extends patent portfolio in China, Japan, and Israel

07 March 2025 | News

Strengthening intellectual property for infectious disease and cancer treatments



US-based biotech firm Indaptus Therapeutics, Inc. has secured new patent approvals in China, Japan and Israel for its Decoy platform. These patents cover the use of Decoy bacteria compositions for preventing or treating Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) – two diseases that continue to pose major global health challenges. The patents also extend to combination therapies with a variety of both approved and investigational treatments.

Dr Michael Newman, Founder and Chief Scientific Officer of Indaptus, commented, "The allowance of these patents in key international markets highlights the potential of our Decoy platform in the fight against chronic infectious diseases. With millions of people affected by HBV and HIV worldwide, expanding our intellectual property reinforces the novelty and therapeutic promise of our approach."

Chronic HBV infections remain a major health concern, especially in Asia. China has approximately 87 million people living with chronic HBV, nearly one-third of all cases worldwide, while Japan has approximately 1.1 – 1.2 million people affected by chronic HBV.

Preclinical studies demonstrated that Indaptus' Decoy bacteria—which are attenuated and killed bacteria designed to stimulate the immune system—produced significant single-agent activity in standard models of chronic HBV and HIV infections.

Patented candidates from Indaptus' Decoy platform have also produced single agent activity and durable, combination-mediated tumor eradication in multiple pre-clinical cancer models and one candidate (Decoy20) is currently being evaluated in a Phase 1 clinical trial in the US for patients with advanced cancers.